Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank at the Jefferies Virtual Global Healthcare Conference  (Replay)
    Tuesday, June 02, 2020 4:00 pm EDT
Toggle Summary Spring Bank Announces Dosing of Inarigivir 400mg In Multiple HBV Studies
-  First Patient Dosed Ahead of Schedule in Inarigivir 400mg CATALYST 2 Trial  -  First Patient Completes Dosing in Inarigivir 400mg Intra-Hepatic Liver Biopsy Study    -  Ongoing Inarigivir + Tenofovir Alafenamide 25mg Co-Administration Trial Expanded to Include Inarigivir 400mg Cohort HOPKINTON,
Toggle Summary Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
HOPKINTON, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into
Toggle Summary Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
HOPKINTON, Mass. , July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein , M.D.,
Toggle Summary Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
HOPKINTON, Mass. , July 01, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has submitted an
Toggle Summary Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
HOPKINTON, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present for
Toggle Summary Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
HOPKINTON, Mass. , June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it would present
Toggle Summary Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
HOPKINTON, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,
Toggle Summary Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigivir + nucleotide analogue fully enrolled – top-line results expected 2H’19 Study results to be presented at Science of HBV Cure
Toggle Summary Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log 10 with a range of 0.5log 10 - 1.4log 10 Inarigivir 400mg rapidly and uniformly
Toggle Summary Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
Conference call to be held on Friday, April 12 at 8:00am EDT HOPKINTON, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases